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Abstract
Background: Human N-acetyltransferase complex B (hNatB) is integrated by hNaa20p (hNAT5/
hNAT3) and hNaa25p (hMDM20) proteins. Previous data have shown that this enzymatic complex
is implicated in cell cycle progression and carcinogenesis. In yeast this enzyme acetylates peptides
composed by methionine and aspartic acid or glutamic acid in their first two positions respectively
and it has been shown the same specificity in human cells.
Methods:  We have silenced hNAA20  expression in hepatic cell lines using recombinant
adenoviruses that express specific siRNAs against this gene and analyzed cell cycle progression and
apoptosis induction after this treatment. Immunopurified hNatB enzymatic complexes from human
cell lines were used for analyzing hNatB in vitro enzymatic activity using as substrate peptides
predicted to be acetylated by NatB.
Results: hNAA20 silencing in hepatic cell lines reduces cell proliferation in a p53 dependent and
independent manner. At the same time this treatment sensitizes the cells to a proapototic stimulus.
We have observed that the hNatB complex isolated from human cell lines can acetylate in vitro
peptides that present an aspartic or glutamic acid in their second position as has been described in
yeast.
Conclusion: hNatB enzymatic complex is implicated in cell cycle progression but it exerts its
effects through different mechanisms depending on the cellular characteristics. This is achievable
because it can acetylate a great number of peptides composed by an aspartic or glutamic acid at
their second residue and therefore it can regulate the activity of a great number of proteins.
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Background
Protein modification is a mechanism for regulate and
improve proteins function and activity, being N-terminal
acetylation one of the most abundant activities. Although
the two cotranslational events, cleavage of the initiator
methionine and N-acetylation, are common and highly
conserved from bacteria to higher eukaryotes, their func-
tion it is not well understood [1,2]. Obviously, the
removal of the initiator residue allows diversity of ami-
noterminal sequences and therefore enhances the func-
tional repertoire of the polypeptide.
N-acetyltransferase complexes are composed by one cat-
alytic subunit and one or several auxiliary subunits. NatB
enzymatic complex is integrated by the catalytic subunit
Naa20p and the auxiliary subunit Naa25p, as has been
observed in yeast and human cells [3-5].
In yeast, proteins with Met-Asp-, Met-Glu-, Met-Asn- and
Met-Met- amino termini constitute potential NatB sub-
strates. However, whereas Met-Asp- and Met-Glu- termini
appear to be acetylated in 100% of the cases, only some of
the experimentally investigated Met-Asn- and Met-Met-
termini have been found to constitute true NatB targets
[6]. In the meantime all mammals proteins with Met-Asn-
and Met-Met- termini analyzed present the methionine
acetylated and consequently they are considered as NatB
substrates [2].
Despite the widespread occurrence of N-terminal acetyla-
tion in eukaryotes, the biological relevance of this protein
modification has only been deduced for a few substrates,
as the tropomyosin and actin. It has been documented
that yeast tropomyosin-1 and actin are NatB-mediated
acetylated being this modification important for the for-
mation of stable and functional actin cables [3,4]. Tropo-
myosin activity is also regulated by N-terminal acetylation
in fission yeast [7] and N-terminal acetylation of Dictios-
telum actin strengthens interaction of actin and myosin
[8]. In addition, actin aminoterminal processing is ligated
to the acetylation of the initial methionine as the removal
of the methionine in class I and class II actins and of the
cysteine in class II actins that occurs in an acetylation-
dependent manner [9,10]. Hence, a proper N-terminal
processing is very important for regulating actin function
[11].
Human NatB complex has been recently characterized
showing that it is composed at least by the catalytic subu-
nit hNaa20p and the auxiliary subunit hNaa25p [5]. The
two main aminoterminal acetyltransferase activities, NatA
and NatB, are important for human cell cycle progression
[5,12], but unlike NatA, there is not an induction of apop-
tosis when NatB is inhibited [5,12,13].
We have extended the analysis of NatB function to two
human hepatocarcinoma cell lines concluding its implica-
tion in cellular proliferation. We have also studied in vitro
hNatB activity identifying some new in vitro substrates and
establishing that not all the peptides with Met-Asp- and
Met-Glu- amino termini are good in vitro hNatB sub-
strates.
Methods
hNAA20 and hNAA25 expression plasmids, siRNAs and 
adenovirus production
hNAA20-CTAP expression plasmid was generated excising
hNAA20 from the pcDNA3-TOPO-TA-hNAA20 plasmid
and inserting it in the plasmid pCTAP (Stratagene, CA,
USA). The plasmid pDEST27-NAA25 was obtained from
Imagenes (Berlin, Germany).
hNAA20 expression in HepG2 and Hep3B cell lines has
been inhibited using recombinant adenoviruses that
express specific siRNAs. These sequences and adenovirus
production have been described previously [12].
Cell culture and infections with the siRNA expressing 
adenoviruses
Human Hela, HepG2, Hep3B and 293 cell lines were pur-
chased from the ATCC and 293 Cre4 cell line was pro-
vided by Dr Hardy. All the cell lines were cultured in
DMEM supplemented with 10% foetal calf serum. Cre4
cells were also supplemented with 500 g/ml G418. All
reagents were from Gibco-BRL (Paisley, UK).
Infections with hNAA20 siRNA expressing adenoviruses
were performed in HepG2 and Hep3B cells. The day prior
to infection 250,000 HepG2 and 150,000 Hep3B cells
were plated in a 6 well plate and infection was performed
in DMEM-2% foetal calf serum at a multiplicity of infec-
tion (MOI) of 10.
Protein extraction and Western Blot Analysis
To extract protein from cultured cells, the cells were col-
lected in 100 l of RIPA solution (150 mM NaCl, 50 mM
Tris pH 7.5, 0.1% SDS, 1% Triton X-100, 0.5% sodium
deoxycholate, 10 mM NaF, 1 mM Na3VO4 and a protease
inhibitor cocktail from Roche). Protein extracts were col-
lected after sonication and centrifugation at 16,000 g for
15 minutes, and supernatants were stored at -80°C.
Cultured cells protein extracts (20 g) were loaded in SDS
polyacrylamide gels and after electrophoresis, the proteins
were transferred to nitrocellulose membranes (Bio-Rad
Laboratories) and detected by incubation with specific
antibodies. Protein bands were visualised using the
enhanced chemiluminescence detection system (Perkin
Elmer, Boston, Massachusetts, USA) and membranes were
autoradiographed.BMC Proceedings 2009, 3(Suppl 6):S4 http://www.biomedcentral.com/1753-6561/3/S6/S4
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Antibodies used were: chicken anti-hNAA20 from Gen-
way Biotech (California, USA), goat anti-GST from Abcam
(Cambridge, UK), mouse anti-GAPDH from Biogenesis
(Bournemouth, UK), rabbit anti-Bcl-2, mouse anti-
Mdm2, mouse anti-p53 (DO-1), goat anti-p21(WAF/
CIP1)(WAF1/CIP1) from Santa Cruz Biotechnology
(Santa Cruz, California, USA), anti-rabbit IgG HRPO from
Cell Signalling (Beverly, Massachusetts, USA), anti-goat
IgG HRPO and anti-mouse IgG HRPO from Sigma, rabbit
anti-IgY from Upstate and rabbit anti-IgY HRPO from
Pierce (Illinois, USA).
Coimmunoprecipitation
GST-hNAA25 and hNAA20-CTAP expressing plasmids
were transfected in Hela cells using linear polyethylen-
imine 25 kDa (Polysciences, Warrington, PA, USA) as
described previously [14]. 48 hours after transfection the
samples were harvested in RIPA buffer and incubated with
anti-Naa20p or anti-GST antibodies to immunoprecipi-
tate the protein complexes.
N-terminal acetyltransferase assay (NAT)
The NAT assay was performed basically as described pre-
viously [15,16] but using hNaa20p or GST-hNaa25p
immunoprecipitated complexes that were incubated with
138 l of 0.2 M K2HPO4 (pH 8.1), 10 l of the substrate
peptide (0.5 mM) and 1 Ci of [3H]acetyl-CoA (99.9
GBq/mmol, GE Healthcare) for 2 hours at 37°C. The sam-
ples were centrifuged and the supernatant was incubated
with SP-Sepharose (50% in 0.5 M acetic acid) for 10 min-
utes on a rotor before washing the SP-Sepharose three
times with acetic acid 0.5 M and once with methanol. The
radioactivity incorporated in the peptides was determined
by scintillation counting.
Cell proliferation assay
HepG2 and Hep3B cells were seeded in 15 mm cover
glasses and infected with siRNA expressing adenovirus
pAdsiRNA2 or pAdsiRNA350 for 24, 48 and 72 hours,
BrdU labeled for 1 hour and processed using the 5-
bromo-2'-deoxyuridine Labeling and Detection Kit I
(Roche Applied Science, Penzberg, Germany) following
the manufacturer's instructions.
Cell cycle analysis
HepG2 and Hep3B cells were harvested after 72 hours of
infection with the adenovirus pAdsiRNA2 or
pAdsiRNA350 and processed using the CycleTEST PLUS
DNA reagent kit (Becton Dickinson) following the manu-
facturer's instructions. Flow cytometric analysis of the dif-
ferent samples was performed using BD FACScalibur flow
cytometer and DNA content was analyzed using the
MODFIT software.
TUNEL Assay
HepG2 and Hep3B cells were incubated in 15 mm cover
glasses and infected with adenovirus pAdsiRNA2 or
pAdsiRNA350 for 48 hours prior adding the proteasome
inhibitor MG132 (5 M) (Calbiochem, Darmstadt, Ger-
many) for an additional 8 hours. Cells were fixed in 4%
phosphate-buffered paraformaldehyde (pH 7.4). TUNEL
assay was performed using the In Situ Cell Death Detec-
tion Kit (Roche Applied Science) according to the manu-
facturer's instructions. Cell apoptosis percentage was
obtained as indicated in cell proliferation assay.
Results and discussion
hNaa20p implication in cellular proliferation
It has been previously reported that hNatB inhibition gen-
erates a reduction of cellular proliferation [5,12]. To
extend this analysis to the effect of hNaa20p inhibition in
human hepatocarcinoma cell lines, we performed siRNA
mediated hNaa20p downregulation infecting HepG2 and
Hep3B cell lines with recombinant adenoviruses that
express specific or unrelated hNAA20  shRNAs. As it is
observed in Figure 1A, 72 hours after viral infection there
is close to a 75% decrease of hNaa20p present in HepG2
and Hep3B cells when hNAA20 siRNA (pAdsiRNA2) is
expressed. Previous data indicate that there is an inhibi-
tion of cell cycle progression when hNatB is inhibited.
Therefore we measured cellular proliferation after
hNAA20 knockdown and observed a clear inhibition in
both cell lines (Figure 1B). This growth arrest is accompa-
nied with an accumulation of cells in the G2 phase of the
cell cycle after a FACS cell analysis (Figure 1C). We have
previously observed the same effect in Hela cells, in con-
trast to the G0/G1 accumulation observed by Starheim et
al [5] after siRNA mediated hNaa20p downregulation in
Hela and CAL-62 cell lines. Interestingly, we observed an
increase of the percentage of cells in G2 phase in Hep3B
after unrelated siRNA (siRNA350) expression, indicating
that adenovirus mediated siRNA expression could be
facilitating G2 phase accumulation. In spite of this effect,
there is no reduction in the rate of proliferation after
siRNA350 expression in Hep3B (Figure 1B). When we
have used another hNAA20 siRNA or unrelated hNAA20
shRNA [12]we have obtained similar results (data not
shown).
Thus hNatB inhibition promotes a reduction in cellular
proliferation in all cell lines tested, according to the effects
of hNatA inhibition [13,17]. It seems therefore that N-ter-
minal acetylation of proteins is an important function for
a proper cell growth and division as has been described
for protein lysine acetylation/deacetylation [18].
The p53 tumour suppressor is a tightly regulated protein
that acts by stopping cell-cycle progression or promoting
apoptosis when cells encounter stress stimuli such asBMC Proceedings 2009, 3(Suppl 6):S4 http://www.biomedcentral.com/1753-6561/3/S6/S4
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oncogene activation or DNA damage [19,20]. For that rea-
son we analyzed HepG2 cellular extracts for p53 accumu-
lation, and 48 hours after siRNA expression there was an
increase in the amount of p53 present in the cells corre-
sponding with the decrease of Naa20p (Fig 2A), as has
been described in Hela cells [12]. As it is shown in Figure
2A, p53 accumulation in HepG2 correlated with a
decrease of Mdm2 and not with p53 Ser15 phosphoryla-
tion as was described in Hela cells [12]. One of the medi-
ators of the response generated after p53 activation is
p21(WAF/CIP1) that is activated in Hela cells but not in
HepG2. Hence hNAA20 downregulation promotes differ-
ent stress signals in Hela and HepG2 cells causing growth
arrest. But this antiproliferative effect can also be p53
independent because hNaa20p downregulation in
Hep3B, a cell line that is p53 deficient [21], induces cell
growth arrest too. Consequently, when we compared Hela
gene expression profile obtained after hNAA20 downreg-
ulation with HepG2 and Hep3B most of the genes
induced in Hela cells were not upregulated in HepG2 and
Hep3B (data not shown). These differences are not
restricted to hNAA20  inhibition in distinct cell lines
because hNAA25 repression causes also cell growth arrest,
but instead of upregulating p21(WAF/CIP1) expression,
as hNAA20 knockdown, there is a clear p21(WAF/CIP1)
reduction [5]. The different molecular responses gener-
ated after hNaa20p downregulation in different cell lines
can be a reflection of the high number of hNatB substrates
(above 10% of total proteome) that can affect cellular
growth according to their acetylation status and the cellu-
lar milieu, as it has been described for histone deacetylase
inhibitors [18]. But we can not exclude the existence of a
common mechanism in all cell lines that we have not
deciphered yet.
hNaa20 knockdown sensitizes the cells to proapoptotic 
stimuli
In many instances inhibition of cellular proliferation is
associated with an increase of apoptosis [22]. Inhibition
of NatB activity in Hela cells sensitizes the cells to a proa-
poptotic stimulus, like the proteasome inhibitor MG132
[12], but it is not associated with an increase of cellular
apoptosis. We observed that hNAA20  knockdown in
HepG2 and Hep3B is not associated with apoptosis
induction (data not shown ) but it sensitizes the cells to
the proapoptotic treatment with MG132 as it is presented
in Figure 2B where there is a clear induction of apoptosis
in HepG2 and Hep3B cells that express hNAA20 siRNA,
siRNA2. This effect correlates in HepG2 with a reduction
Effects on HepG2 and Hep3B p53 expression and cell death  after siRNA mediated hNAT5/hNAT3 knockdown Figure 2
Effects on HepG2 and Hep3B p53 expression and cell 
death after siRNA mediated hNAT5/hNAT3 knock-
down. A. Western Blot of Mdm2, p53, Bcl-2 and p21(WAF/
CIP1) 24, 48 and 72 hours after infection using GAPDH as 
loading control. B. Apoptotic cell death quantification using 
TUNEL technology after hNaa20p expression inhibition for 
48 hours and incubated with the proteasome inhibitor 
MG132 for additional 8 hours. Representative experiment of 
at least three independent experiments.
Effects of siRNA mediated hNAA20 expression inhibition in  HepG2 and Hep3B cellular proliferation Figure 1
Effects of siRNA mediated hNAA20 expression inhi-
bition in HepG2 and Hep3B cellular proliferation. A. 
Western Blot analysis of hNaa20p in uninfected or infected 
cells with adenoviruses which express siRNA2 or control 
siRNA (siRNA350) for 24, 48 and 72 hours. B. Cellular pro-
liferation quantification after siRNA mediated hNAA20 
knockdown for 33, 48 and 72 hours measured as the per-
centage of cells that incorporate BrdU. Representative 
experiment of at least three independent experiments. C. 
Cell cycle flow cytometry analysis of control and hNAA20 
downregulated expression in HepG2 and Hep3B cells 72 
hours after adenovirus infection. The data represent the 
mean value and standard deviation of the cell percentage 
present in each phase of the cell cycle from four independent 
experiments.BMC Proceedings 2009, 3(Suppl 6):S4 http://www.biomedcentral.com/1753-6561/3/S6/S4
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of BCL2 (Figure 2A), which is an important antiapoptotic
molecule [23].
We have observed also that Hep3B cell line is more sensi-
tive to MG132 treatment as Hep3B cells that express the
unrelated siRNA present some sensitivity to MG132. This
is Hep3B specific because a prolonged exposure of the
cells to this proapoptotic stimulus induces an apoptotic
cell death that it is not observed in Hela and HepG2 cells
(data not shown). These findings are also reminiscent of
the increased sensitivity to environmental stress when
yeast strains were deleted of yNatB enzymatic complex
(naa20-, naa25-) [3,4,6].
Characterization of the in vitro N-acetyltransferase 
activity of the NatB complex
NAT enzymatic complexes are composed by a catalytic
subunit and one or several accessory subunits. In the case
of hNatA there are two possible catalytic subunits [24]
and several accessory subunits [25] but hNatB complex is
formed by the catalytic subunit hNaa20p that interacts
with hNaa25p to generate an active hNatB complex [5].
We have coexpressed hNaa20p with a carboxi terminal
protein tag (CTAP) and hNaa25p fused to GST in Hela
cells, detecting an interaction between both fusion pro-
teins (Figure 3A) as it has been described in yeast and
human cells before [3-5]. In order to determine if the
hNatB enzymatic complex immunopurified with the GST
antibodies is enzymatically active we performed an in vitro
acetyltransferase assay using as substrate a peptide corre-
sponding to human tropomyosin-1 amino terminus, that
has been demonstrated to be a hNatB substrate [12]. We
observed that immunopurified hNatB complexes, using
GST-Naa25p as bait, rescue active enzymatic complexes
that acetylate efficiently the tropomyosin-1 aminotermi-
nal peptide, as well as the hNatB complexes immunopu-
rified with a hNaa20p specific antibody (Figure 3B).
Thereafter we analyzed if the immunopurified hNatB
complexes were able to acetylate p53 aminoterminal pep-
tide, as this protein is a potential NatB substrate based on
its first two amino acids (Met-Glu-). Surprisingly, none of
the purified hNatB complexes acetylated this peptide.
In order to characterize in more detail hNatB in vitro
acetyltransferase activity we purified enzymatic complexes
with the hNaa20p antibody from Hela cells as this has
resulted the most efficient isolation method (Figure 3A).
A set of peptides corresponding to the aminoterminal
sequences from proteins with a glutamic or aspartic acid
after the initial methionine, as those proteins are pre-
dicted to be NatB substrates [1,2], were used in the hNatB
in vitro assay. Only 5 in 19 analyzed peptides were not
hNatB acetylated, being good substrates both Met-Asp
and Met-Glu- peptides (Table 1). However all the eukary-
otic proteins with an aspartic or glutamic acid at position
+2 analyzed so far are N-terminaly acetylated [2]. This
indicates that the in vitro hNatB acetylation activity is not
completely reproducing the in vivo activity because we are
missing some components or characteristics necessary for
a perfect hNatB in vitro function. But as we are using as
substrates 20 amino acid peptides they can lack some
Table 1: Identification of hNatB in vitro substrates.
PEPTIDE CPM PEPTIDE CPM
BAXA 86 DCUP 51
BRCA1 384 KAD1 502
CASP8 457 B3AT 72
CASP9 7323 CRBA1 119
CDK3 3489 PTN1 2931
CDK8 2665 PPLA 2741
FADD 95
TNNC1 82 No-peptide 74
1433E 1763
CRYAB 4077
NAT2 5363
MT1A 1309
RS28 1402
Immunopurified hNatB complexes with anti-hNaa20p antibody were 
used to identify 20 amino acids length peptides with Met-Asp- (MD-) 
or Met-Glu- (ME-) as first two amino acids that are in vitro acetylated 
by hNatB. The results are representative of at least two independent 
experiments.
hNatB purification and enzymatic activity Figure 3
hNatB purification and enzymatic activity. A. Coim-
munoprecipitation of GST-hNaa25p and hNaa20p-CTAP or 
GST-hNaa25p and hNaa20p. B. NAT activity of immunopre-
cipitated hNatB complexes from Hela cells overexpressing 
GST-hNaa25p and hNaa20p-CTAP with anti-hNaa20p or 
anti-GST antibodies. Human tropomyosin-1 or p53 aminote-
rminal peptides synthesized by Dr Francisco Borrás-Cuesta 
at CIMA University of Navarra as previously described [27] 
were used as substrates. The results are representative of 
three independent experiments.BMC Proceedings 2009, 3(Suppl 6):S4 http://www.biomedcentral.com/1753-6561/3/S6/S4
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structural information necessary for being hNatB sub-
strate as the yeast NatD enzymatic activity [26]. Further-
more, we can not exclude the existence of unknown NATs
with an hNatB overlapping substrate specifity in vivo.
In order to prove the relevance of the first two aminoter-
minal amino acids in hNatB substrates we substituted
human tropomosin-1 first, second or both aminoacids by
an alanine. As it is observed in Table 2, the replacement of
the second amino acid abolishes its nature as hNatB sub-
strate but not the substitution of the first amino acid. Thus
the second residue is the most important for determining
hNatB substrates and this enzymatic activity is not
restricted to methionine acetylation as it can acetylate a
different residue such as alanine.
Actin N-terminal processing is very important for a proper
actin function [11] being N-terminal acetylation a signifi-
cant step in this procedure [9,10]. Therefore we extended
the analysis to the human -actin aminoterminal peptide
with the same substitutions as the tropomyosin peptide.
Surprisingly, all the mutated -actin peptides were as
good substrates as the original sequence (Table 2). Conse-
quently, in some cases there are other amino acids besides
the first two aminoterminal that dictate the competence
of a peptide as hNatB substrate.
Conclusion
In conclusion, we have determined that hNatB enzymatic
complex is necessary for a proper cell cycle progression
and resistance to proapoptotic stimuli in hepatic cell lines
as has been observed before in other cell types. hNaa20p
downregulation induces cell growth arrest in a p53
dependent and independent manner. hNatB acetylates in
vitro  most of the peptides with Met-Asp- or Met-Glu-
amino termini, being more important the aspartic or
glutamic acid than the initial methionine for a proper
acetylation.
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